Invitrogen™ CD38 Monoclonal Antibody (HIT2), PerCP

Description

This antibody reacts with an extracellular epitope of CD38, a 45 kDa type II transmembrane glycoprotein strongly expressed mainly on plasma cells and activated T and B lymphocytes; it is an antigenic marker of lymphoid cells. Its binding is blocked by daratumumab.

CD38 (NAD+ glycohydrolase) is a type II transmembrane glycoprotein able to induce activation, proliferation and differentiation of mature lymphocytes and mediate apoptosis of myeloid and lymphoid progenitor cells. CD38 functions as a multi-catalytic ectoenzyme serving as ADP-ribosyl cyclase, cyclic ADP-ribose hydrolase and possibly NAD+ glycohydrolase or as a cell surface receptor. Antibodies to CD38 are useful in subtyping of lymphomas and leukemias, detection of plasma cells (i.e. identification of myelomas), and as a marker for activated B and T cells. CD38 participates in cell adhesion, signal transduction and calcium signaling. Further, CD38 is expressed at high levels in the pancreas, liver, kidney, malignant lymphoma and neuroblastoma. Diseases associated with CD38 dysfunction include chronic lymphocytic leukemia and Richter's Syndrome.